On November 15, 2018, Syros Pharmaceuticals, Inc. (the "Company") reported that it held a conference call and webcast in which the Company’s management reviewed a slide presentation describing, among other things, data from the dose-escalation portion of the Company’s Phase 1 clinical trial of SY-1365 (Presentation, Syros Pharmaceuticals, NOV 15, 2018, View Source [SID1234531470]). This slide presentation is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!